운전자본 팽창 → 현금 고갈 → 유동성 위기
Warning순운전자본이 +30.8% 팽창하며 현금이 묶이고 있다. 영업CF/순이익 비율이 -76%로 이익 대비 현금 회수가 부족하고, 유동비율도 1.95에서 1.63로 하락했다.
Evidence
순운전자본 YoY +30.8%영업CF/순이익 -76%유동비율 1.95→1.63
L&K Biomed
156100 · KOSDAQ₩4,240+9.84%
2026-09-04 closeL&K Biomed last closed at ₩4,240 (+9.84%) on 2026-09-04. Signals today: MACD bullish cross. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
PER 9.03 · PBR 2.07 — own-history percentile 100/100 · 76/100
Open self-history band
PER100/100
PBR76/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.95
Distress
Grey
Safe
- Altman Z''
- 0.95
- Beneish M-Score
- -1.25
- Sloan accrual
- 20.68%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -21%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Revenue qualityWarning
매출채권 증가율이 매출 증가율의 1.5배 초과 (3기 연속) — 매출 인식 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 140% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 7.5%
- Interest coverage
- 1x
- Return on equity (ROE)
- 22.9%
Operating margin −5pp
Interest coverage riskInterest coverageBase 1x adverse case 0.3x
Return on equity (ROE)Base 22.9% adverse case -4.2%
Revenue −15%
Interest coverage riskInterest coverageBase 1x adverse case 0.9x
Return on equity (ROE)Base 22.9% adverse case -0.9%
Interest rate +2pp
Interest coverage riskInterest coverageBase 1x adverse case 0.8x
Return on equity (ROE)Base 22.9% adverse case -1.9%
Interest coverage limit
Current margin 0ppInterest coverage limit at an operating margin of 7.4%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-12Suppliers disclosed by the company in its 2026-03-12 annual report.
Suppliers without disclosed amount
USDPEEKOPTIMARODELI
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 강국진12.22%2026-08-11 · 증감 +0.03%p
Connections
AI-extracted related companies · for reference
Competitors
오쏘픽스 메디컬뉴베이시브조디악 메디컬
Same theme
메디트로닉 인스티튜트/미국 척추 수술 시장정형외과 임플란트
Recent filings
L&K Biomed's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About L&K Biomed
- What technical signals does L&K Biomed (156100) have?
- L&K Biomed current technical signals: no active technical signal.
- Is L&K Biomed a cup-and-handle pattern?
- No. L&K Biomed has no valid cup-and-handle signal right now.
- What are L&K Biomed's financials and valuation?
- L&K Biomed's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy